Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien Gains BIS Anesthesia Monitoring Technology In Aspect Medical Buy

This article was originally published in The Gray Sheet

Executive Summary

Covidien is adding brain monitoring technology to its lineup through the $210 million acquisition of Aspect Medical Systems, announced Sept. 28

You may also be interested in...



Covidien Expands Oximetry Biz With Somanetics Acquisition

Covidien will expand its oximetry offerings through the purchase of Invos patient monitor manufacturer Somanetics for $250 million

Covidien Expands Oximetry Biz With Somanetics Acquisition

Covidien will expand its oximetry offerings through the purchase of Invos patient monitor manufacturer Somanetics for $250 million

Covidien Augments Endomechanical Biz With Stapler, Single-Incision Devices

Covidien expects the recent slowdown in growth of its endomechanical business to dissipate with the launch of new products this year, the company said during its April 21 second-quarter earnings call

Related Content

Topics

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel